Drakenterprises
CardiologyDiabetesFamily MedicineEmergencyOrthopaedicsOtolaryngologyOncologyCross-cutting

Not clinical advice. Clinical Evidence is a current-awareness feed. It is not a clinical decision-support system, not medical advice, and not a substitute for clinical judgment, institutional protocols, or the original sources. Full text, NCCN recommendations, and Cochrane review bodies are not reproduced here.

Home · cross-cutting

NatureArticle

Biomarkers that predict improved outcomes after perioperative immune-based therapy for lung cancer.

Nature · 09/02/2026

Publication types: News

PubMed abstract / permitted excerpt

Nature, Published online: 02 September 2026; doi:10.1038/d41586-026-02486-5 Comprehensive exploratory analyses of biomarkers were done in the phase III CheckMate 77T study of pre- and post-surgical treatment with the immunotherapy nivolumab in individuals with surgically resectable non-small-cell lung cancer. The analyses indicate that pre-surgical clearance of circulating tumour DNA, among other

Full-text bodies are not stored. PubMed metadata and official TOC RSS. No full-text republication.

Clinical Evidence